IMVT - Company ID 0001764013
The table below shows Immunovant, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -$106.11M | -$83.33M |
| Capital expenditure | $8.00K | $759.00K | $360.00K | $197.00K | $254.00K | $210.00K |
| Investing cash flow | -$8.00K | -$759.00K | -$360.00K | -$197.00K | -$254.00K | -$210.00K |
| Dividends paid | - | - | - |
Immunovant, Inc. reported operating cash flow of -$407.31M for fiscal year 2026. That is down 8.4% from -$375.87M in fiscal 2025. Over the 8 fiscal years shown, operating cash flow declined from -$28.55M (FY 2019) to -$407.31M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $595.76M | $454.49M | $472.43M | $70.89M | $200.13M | $383.11M |